Literaturverzeichnis

ACCP/SCCM Consensus conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874

Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, Nisperos B, O’Quigley J, Ramberg R, Sanders JE, Stewart P, Storb R, Sullivan KM, Witherspoon RP, Thomas ED, Hansen JA (1989) Effect of HLA compatibility on engraf t ment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320: 197-204

Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M, Rapa S, Talevi N, Galimberti M, Nesci S (1996) Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 87: 3494-3499

Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177-186

Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D (2001) Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Ma r row Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 7: 473-485

Appelbaum FR (1987) Allogeneic hematopoietic stem cell transplantation for acute le u kemia. Semin Oncol 24: 114-123

Arnold R, Massenkeil G, Bornhäuser M, Ehninger G, Beelen DW, Fauser AA, Hege n bart U, Hertenstein B, Ho AD, Knauf W, Kolb HJ, Kolbe K, Sayer HG, Schwerdtfeger R, Wandt H, Hoelzer D (2002) Nonmyeloablative stem cell tran s plantation in adults with high-risk ALL may be effective in early but not in a d vanced disease. Leukemia 16: 2423-2428

Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PF, Gramatzki M, von Jü r genson S, Wandert T, Patzelt T, Reitz and DGCIN (German Cooper a tive Renal Carcinoma Chemo-Immunotherapy Trials Group) (2001) IL-2 in combination with IFN- alpha and 5-FU ve r sus tamoxifen in metastatic renal cell carc i noma: long-term results of a controlled randomized clinical trial. Br J Cancer 85: 1130-1136

Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, Einsele H, Ni e meyer C, Benda N, Faul C, Kanz L, Niethammer D, Klingebiel T (1998) Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of r e lapse after allogeneic BMT. Bone Marrow Transplant 21: 487-495

Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P, Niethammer D, Beck JF (1999) Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single ce n ter experience of 12 children. Leukemia 13: 2079-2086

Barnes DW, Loutit JF (1957) Treatment of murine leukaemia with x-rays and homol o gous bone marrow. Br J Haematol 3; 241-252

Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N (2003) New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program): 350-371

Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buc k ner CD, Storb R, Thomas ED, Hansen JA (1985) Marrow tran s plantation from related donors other than HLA-identical siblings. N Engl J Med 313: 765-771

Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers ME, Lilleby K, Chauncey TR, Storb R, Appelbaum FR (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical rel a tives in patients with hematologic cancers. N Engl J Med 344: 175-181

Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Boiron JM, Schuller MP, Moatti JP, Michallet M (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage le u kemia: a report from the S o ciete Francaise de Greffe de Moelle. J Clin Oncol 18: 537-546

Blin N, Stafford DW (1976) A general method for isolation of high molecular weight DNA from e u karyotes. Nucleic Acids Res 3: 2303-2308

Bornhäuser M, Kiehl M, Siegert W, Schetelig J, Hertenstein B, Martin H, Schwerdtfeger R, Sayer HG, Runde V, Kröger N, Theuser C, Ehninger G; Cooperative German Transplant Study Group (2001) Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol 115: 119-124

Bow EJ (1998) Infection risk and cancer chemotherapy: The impact of the chemother a peutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 41: 1-5

Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, Corradini P (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99: 4234-4236

Buckner CD, Clift RA, Fefer A, Lerner KG, Neiman PE, Storb R, Thomas ED (1974) Marrow transpla n tation for the treatment of acute leukemia using HL-A-identical siblings. Transplant Proc 6: 365-366

Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O’Gorman P, Cha k raverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DWv (2002) High incidence of cytomegalovirus infection after nonmy e loablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstit u tion. Blood 99: 4357-4363

Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002) Limiting transplant a tion-related mortality following unrelated donor stem cell transplantation by using a nonmyeloa b lative conditioning regimen. Blood 99: 1071-1078

Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG (2003) Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21: 884-890

Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ (1999) Engraftment kinetics after nonmy e loablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94: 3234-3241

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett J (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750-758

Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K (1990) Allogeneic marrow transplantation in p a tients with acute myeloid leukemia in first remission: A randomised trial of two i r radiation regimens. Blood 76: 1867-1871

Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15: 433-444

Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, D o dero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M (2002) Reduced-intensity conditioning fo l lowed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic maligna n cies. Blood 99: 75-82

Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187-220

Davies S, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, Nademanee A, Noreen H, King R, Confer D, Kernan NA (2000) Engraftment and survival after unrelated-donor bone marrow tran s plantation: a report from the national marrow donor program. Blood 96: 4096-4102.

Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, Olavarria E, van Rhee F, Kanfer E, A p perley JF, Goldman JM (2000) Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allograf t ing for chronic myeloid leukemia. Blood 95: 67-71

Deeg HJ, Flournoy N, Sullivan KM, Sheehan K, Buckner CD, Sanders JE, Storb R, Witherspoon RP, Thomas ED (1984) Cataracts after total body irradiation and marrow transplantation: a sparing e f fect of dose fractionation. Int J Radiat Oncol Biol Phys 10: 957-964

Deutsches Register für Stammzelltransplantationen (DRST). Jahresbericht 2000/2001 www.drst.de

Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, van Biezen A, Michallet M, Niederwieser D on behalf of the Chronic Leukemia Working Party of the EBMT (2003a) Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17: 841-848

Dreger P, van Biezen A, Brand R, Esteve J, Martino R, Deliliers GL, Hansz J, Fine J, Kimby E, Milligan D, Michallet M, Niederwieser DW (2003b) Reduced-intensity conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL: A retrospective study on 448 patients. Blood 102: 197a [abs. 689]

Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, Böck G, Gassner C, Schiller L, Petersen F, Niederwieser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast ca n cer. Blood 88: 1501-1508

Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW (1999) The risk of r e sidual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is r e duced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 94: 384-389

Fairlamb DJ (1981) Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dom i nant metastasis and review of the world literature. Cancer 47: 2102-2106

Ferrara JL, Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324: 667-674

Ferrara and Antin (1998) The Pathophysiology of Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ. Hematopoietic Cell Transplantation. 2nd ed. Blac k well Science, Malden, MA, 305-315

Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belld e grun AS (1999) Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymph o cytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17: 2521-2529

Fredriksson M, Barbany G, Liljedahl U, Hermanson M, Kataja M, Syvänen A-C (2004) Assessing hem a topoietic chimerism after allogeneic stem cell transplantation by multiplexed SNP genotyping u s ing microarrays and quantitative analysis of SNP alleles. Leukemia 18: 255-266

Fukuda T, Hackman RC, Guthrie KA, Sandmaier BM, Boeckh M, Maris MB, Maloney DG, Deeg HJ, Martin PJ, Storb RF, Madtes DK (2003) Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional cond i tioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102: 2777-2785

Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R (1997) Engraf t ment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89: 4531-4536

Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recip i ents of marrow from HLA-matched sibling donors. Transplantation 18: 295-304

Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M, Ganser A, Kneba M, Langer W, Lipp T, Ludwig W-D, Maschmeyer G, Roeder H, Thiel E, Weiss A, Messerer D (2000) Trea t ment of adult ALL according to protocols of the German multicenter study group for adult ALL (GMALL). Hematol Oncol Clin North Am 14: 1307-1325

Goulmy E (1997) Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157: 125-140

Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A for the Accreditation Committee of the Eur o pean Group for Blood and Marrow Transplantation (EBMT) (2002) Increasing use of reduced i n tensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant 30: 813-831

Greinix, HT, Nachbaur, D, Krieger, O, Eibl M, Knöbl P, Kalhs P, Lutz D, Linkesch W, Niederwieser D, Hinterberger W, Lechner K, Rosenmayr A, Gritsch B (2002) Fa c tors affecting long-term outcome after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia: a retr o spective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Hematol 117: 914-923

Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, Schattenberg A, Kolb HJ, Ljungman P, Devergie A, Bacigalupo A, Gomez M, Michallet M, Elmaagacli A, Gratwohl A, Apperley J, Niederwieser D on behalf of the Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation (2002) Donor lymphocyte infusion for relapsed chronic myelog e nous leukemia: prognostic relevance of the initial cell dose. Blood 100: 397-405

Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersäll P, Pisa P, Martola J, Albini N, Wernerson A, Söderberg M, Remberger M, Thörne A, Ringdén O (2003) Low-intensity conditioning and hem a topoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31: 253-261

Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara J (1997) Total body irr a diation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90: 3204-3213

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334: 494-500

Holler E (2002) Cytokines, viruses, and graft-versus-host disease. Opin Hematol 9: 479-484

Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Rin g den O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562

Horowitz MM, Rowlings PA (1997) An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol 4: 395-400

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751

Huss R, Deeg HJ, Gooley T, Bryant E, Leisenring W, Clift R, Buckner CD, Martin P, Storb R, Appe l baum FR (1996) Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 18: 767-776

International Bone Marrow Transplant Registry (IBMTR) Database (2003) Current use and outcome of blood and marrow transplantation 2003 www.ibmtr.org

Jacobson LO, Simmons EL, Marks EK, Eldredge JH (1951) Recovery from radiation injury. Science 113: 510-511

Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, Mc Sweeney PA, Little MT, Corey L, Storb R (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloabl a tive allogeneic stem cell transplantation, a matched control study. Blood 99: 1978-1985

Kalbfleisch JD and Prentice RL (1980) The statistical analysis of failure time data. J Wiley, New York

Kaplan EL and Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481

Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O’Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R (1998) Tran s plant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemothe r apy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16: 2817-2824

Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljun g man P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H for the European Group for Blood and Marrow Tran s plantation Working Party Chronic Leucemia (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041-2050

Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuk F, Wittkowsky G, Schmitz N, Zander AR (2002) Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplant a tion-related mortality. Blood 100: 3919-3924

Krüger W, Russmann B, Kröger N, Salomon C, Ekopf N, Elsner HA, Kaulfers PM, Mack D, Fuchs N, Durken M, Kabisch H, Erttmann R, Zander AR (1999) Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 23: 589-597

Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D, Peters C, Matthes-Martin S, Lawitschka A, Gadner H (2001) Analysis of chimerism within specific leukocyte subsets for d e tection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transpla n tation. Leukemia 15: 307-310

Ljungman P (2002) Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 118: 44-57

Lorenz E, Uphoff D, Reid TR, Shelton E (1951) Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 12: 197-201

Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O’Reilly RJ (1995) Adoptive immun o therapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: sep a ration of graft-versus-leukemia responses from graft-versus-host disease. Blood 86: 1261-1268

Mapara MY, Kim Y-M, Wang S-P, Bronson R, Sachs DH, Sykes M (2002) Donor ly m phocyte infusions mediate superior graft-versus-leukemia effects in mixed co m pared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100: 1903-1909

Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE, Sullivan KM, Storb R, Thomas ED, Witherspoon RP, Lomen P, Hannigan, Ha n sen JA (1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76: 1464-1472

Massenkeil G, Genvresse I, Reich G, le Coutre P, Rackwitz S, Dörken B, Arnold R (2002) Complications after nonmyeloablative stem cell transplantation (NST) in acute leukemias. Onkologie 25: 100 [abs. 344]

Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dörken B, Arnold R (2002) Basiliximab is well tole r ated and effective in the treatment of steroid-refractory acute graft-versus-host disease after a l logeneic stem cell transplantation. Bone Marrow Transplant 30: 899-903

Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G, Dörken B, Arnold R (2003) R e duced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leuk e mias if complete donor chimerism can be achieved. Bone Marrow Transplant 31: 339-345

Mc Sweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic m a lignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400

Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE; Infectious Diseases Soc i ety of America; American College of Critical Care Medicine; Society for Healthcare Epidemio l ogy of America (2001) Guidelines for the management of intravascular catheter-related infe c tions. Clin Infect Dis 32: 1249-1272

Mielcarek M, Martin PJ, Leisenring W, Flowers M, Maloney DG, Sandmaier BM, Maris MB, Storb R (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102: 756-762

Mickisch GHJ, Garin A, van Pappel H, de Prijck L, Sylvester R, and members of the European Organis a tion for Research and Treatment of Cancer (EORTC) Gen i tourinary Group (2001) Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon-alpha alone in metastatic renal-cell-carcinoma: a randomised trial. Lancet 358: 966-970

Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I, Chabannon C, Bouabda l lah R, Ladaique P, Collet L, Zandotti C, Maraninchi D, Blaise D (2000) High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 26: 251-255

Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335: 865-75

Nagy M, Massenkeil G, Anders P, Hahne C, Krüger C, Otremba P, Arnold R, Geserick G (2000) Short Tandem Repeat Analysis to Monitor Chimerism after Allogeneic Stem Cell Transplantation. In: Sensabaugh GF, Lincoln PJ, Olaisen B ( eds ). Progress in Forensic Genetics 8: Proceedings of the 18th International ISFH Congress. San Francisco, CA; 561-563

National Marrow Donor Program (2003) www.marrow.org

Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D, M e unier F, De Pauw B (1998) Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26: 1098-1103

Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic my e loid leukaemia in first chronic phase. Blood 101: 441-445

Orsini E, Alyea EP, Chillemi A, Schlossman R, McLaughlin S, Canning C, Soiffer RJ, Anderson KC, Ritz J (2000) Conversion to full donor chimerism following donor lymphocyte infusion is assoc i ated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant 6: 375-386

Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevi l lard S (2002) Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correl a tion with clinical outcome. Anticancer Res 22: 121-128

Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M, Prentice G, Garg M, Yin JA, Byrne J, Russell NH, Mufti GJ (2002) Allogeneic stem cell transplantation in the myelodysplastic sy n dromes: interim results of outcome following reduced-intensity conditioning compared with sta n dard preparative regimens. Br J Haematol 119: 144-154

Parmar MKB and Machin D (1996) Survival analysis – a practical approach. J Wiley, New York.

Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zimbelli A, Giralid E, Landonio G, Locatelli F, Siena S, della Cuna GR (2002) Allogeneic blood stem cell transpla n tation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94: 2409-2415

Porter DL, Collins RH Jr, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH (1999) Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 5: 253-261

Porter DL, Collins RH Jr, Hardy C, Kernan NA, Drobyski WR, Giralt S, Flowers ME, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R, Antin JH (2000) Treatment of relapsed leukemia a f ter unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95: 1214-1221

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Co n sensus conference on acute GvHD grading. Bone Marrow Transplant 15: 825-828

Reisner Y, Martelli MF (1995) Bone marrow transplantation across HLA barriers by increasing the nu m ber of transplanted cells. Immunol Today 16: 37-40

Riddell SR, Greenberg PD (1998) Adoptive immunotherapy with antigen-specific T cells. In: Thomas ED, Blume KG, Forman SJ. Hematopoietic Cell Transplantation. 2nd ed. Blackwell Science, Malden, MA, 327-341

Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bac i galupo A, Frassoni F, Gorin NC (1996) Graft-versus-leukemia effect in allogeneic marrow tran s plant recipients with acute leukaemia is maintained using cyclosporin A combined with met h otrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 18: 921-929

Rini BI, Zimmermann T, Stadler WM, Gajewski TF, Vogelzang NJ (2002) Allogeneic stem-cell tran s plantation of renal cell cancer after nonmyeloablative chemothe r apy: feasibility, engraftment, and clinical results. J Clin Oncol 20: 2017-2024

Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, T o palian SL, Simonis TB, Rosenberg SA, Marincola FM (1995) Quantitative correl a tion between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55: 149-157

Roigas J, Deger S, Taymoorian K, Wille AH, Johannsen M, Turk I, Schnorr D, Loening SA (2003) E f fects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma - results of a retrospective analysis. Cancer Biother Radiopharm 18: 157-163

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897

Sandmaier BM, Maris M, Maloney DG, Gooley TA, Stuart MJ, Hegenbart U, Sahebi F, Chauncey T, Agura E, Bruno B, Mc Sweeney PA, Maziarz R, Pulsipher M, Epner E, Little MT, Forman SJ, Niederwieser DW, Blume KG, Storb R (2003) Low-dose total body irradiation (TBI) conditio n ing for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience. Blood 102: 78a [abs. 264]

Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343-346

Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A (1998) Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21: 995-1003

Shank B, O'Reilly RJ, Cunningham I, Kernan N, Yaholom J, Brochstein J, Castro-Malaspina H, Kutcher GJ, Mohan R, Bonfiglio P (1990) Total body irradiation for bone marrow transplantation: the Memorial Sloan-Kettering Cancer Center e x perience. Radiother Oncol 18: 68-81

Sharabi Y, Sachs DH (1989) Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 169: 493-502

Shlomchik WD, Couzens MS, Tang CB, NcNiff J, Robert ME, Liu J, Shlomchik MJ, E m erson SG (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285: 412-415

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED (1980) Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 69: 204-217

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Acke r stein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow tran s plantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-763

Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M (2000) Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic mali g nancies. Biol Blood Marrow Transplant 6: 309-320

Stewart FM, Zhong S, Wuu J, Hsieh C, Nilsson SK, Quesenberry PJ (1998) Lymphohematopoietic e n graftment in minimally myeloablated hosts. Blood 91: 3681-3687

Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, Doney K, Longton G, Hansen J, Hill R, Loughran T, Martin P, Singer J, Sanders J, Ste w art P, Sullivan K, Witherspoon R, Thomas ED (1989a) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for le u kemia: long-term follow-up of a controlled trial. Blood 73: 1729-1734

Storb R, Raff RF, Appelbaum FR, Graham TC, Schuening FG, Sale G, Pepe M (1989b) Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 74: 1139-1143

Storb R, Yu C, Mc Sweeney P (1998) Mixed chimerism after transplantation of allog e neic hematopoietic cells. In: Thomas ED, Blume KG, Forman SJ. Hematopoietic Cell Transplantation. 2nd ed. Blackwell Science, Malden, MA, 287-295

Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, Kiem HP, Mc Sweeney P, Seidel K, Georges G, Zaucha JM (1999) Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 94: 1131-1136

Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T (1991) Chronic graft-versus-host disease and other late complications of bone ma r row transplantation. Seminars in Hematology 28: 250-259

Sureda A, Robinson S, de Elvira CR, Taghipour G, Carella AM, Mackinnon S, Boogaerts M, Caballero D, Michallet M, Russel N, Schmitz N (2003) Non myeloablative allogeneic stem cell transplant a tion significantly reduces transplant r e lated mortality in comparison with conventional allogeneic transplantation in r e lapsed or refractory Hodgkin’s disease: results of the European Group for Blood and Marrow Transplantation. Blood 102: 198a [abs. 692]

Sykes M, Szot GL, Swenson KA, Pearson DA (1997) Induction of high levels of allogeneic hematopo i etic reconstitution and donor-specific tolerance without myelosu p pressive conditioning. Nat Med 3: 783-787

Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR (1999) Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma e f fects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353 (9166): 1755-1759

Thiede C, Florek M, Bornhäuser M, Ritter M, Mohr B, Brendel C, Ehninger G, Neubauer A (1999) Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 23: 1055-1060

Thomas ED (1990) Total body irradiation regimens for marrow grafting. Int J Radiat Oncol Biol Phys 19: 1285-1288

Trentin JJ (1956) Mortality and skin transplantability in X-irradiated mice receiving isologous, homol o gous or heterologous bone marrow. Proc Soc Exp Biol Med 92: 688-693

Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Ande r lini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditio n ing regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102: 3829-3836

Visani G, Bernasconi P, Boni M, Castolid GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S (2001) The prognostic value of cytogenetics is reinforced by the kind of i n duction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients. Leukemia 15: 903-909

Wald A, Leisenring W, van Burik JA, Bowden RA (1997) Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175: 1459-1466

Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allog e neic-marrow grafts. N Engl J Med 300: 1068-1073

Yu C, Storb R, Mathey B, Deeg HJ, Schuening FG, Graham TC, Seidel K, Burnett R, Wagner JL, Shu l man H, Sandmaier BM (1995) DLA-identical bone marrow grafts after low-dose total body irr a diation: effects of high-dose corticosteroids and cy c losporine on engraftment. Blood 86: 4376-4381

Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, Santos E, Storb R (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91: 2581-2587